ERBB2 and cancer: However, TRIEN treatment lead to the identification of two distinct cancer cell subtypes: Triple Negative (i.e., MDA-MB-231 and SUM159) and the luminal A (i.e., T47D) cells versus HER2 overexpressing cells (i.e., SK-BR-3).